论文部分内容阅读
目的探讨Survivin和Sp1在非小细胞肺癌(Non-Small Cell Lung Cancer,NSCLC)组织中的表达与组织分化程度、淋巴结转移和临床分期的关系。方法采用免疫组织化学SP法检测NSCLC患者120例手术标本和良性肺疾病患者40例手术标本中Survivin和Sp1的表达。结果NSCLC组织中Survivin和Sp1的阳性表达率分别为81.6%(98/120)和62.5%(75/120);良性肺疾病组织中阳性表达率分别为无表达和7.5%(3/40),Survivin和Sp1在组织分化程度差、有淋巴结转移和临床分期为三期的NSCLC中表达显著升高;且二者表达呈正相关(rs=0.355,P=0.005)。结论Survivin和Sp1在NSCLC组织中均有高表达,且与组织分化程度、淋巴结转移和临床分期密切相关。
Objective To investigate the expression of Survivin and Sp1 in non-small cell lung cancer (NSCLC) and its relationship with the degree of tissue differentiation, lymph node metastasis and clinical stage. Methods Immunohistochemical SP method was used to detect the expression of Survivin and Sp1 in 120 surgical specimens of NSCLC patients and 40 surgical specimens of patients with benign lung disease. Results The positive rates of Survivin and Sp1 expression in NSCLC tissues were 81.6% (98/120) and 62.5% (75/120), respectively. The positive expression rates of Survivin and Sp1 in NSCLC tissues were 7.5% (3/40) Survivin and Sp1 were significantly up-regulated in NSCLC with poorly differentiated tissue, with lymph node metastasis and clinical stage Ⅲ, with a positive correlation between them (rs = 0.355, P = 0.005). Conclusion Both Survivin and Sp1 are highly expressed in NSCLC tissues, and are closely related to the degree of differentiation, lymph node metastasis and clinical stage.